The effect of bamboo extract on hepatic biotransforming enzymes – Findings from an obese–diabetic mouse model

Cheryl L.K. Koide, Abby C. Collier, Marla J. Berry, Jun Panee

Aim of the study: Bamboo leaves are used as a component in traditional Chinese medicine for the anti-inflammatory function. Our previous studies have demonstrated that an ethanol/water extract from Phyllostachys edulis ameliorated obesity-associated chronic systemic inflammation in mice, and therefore relieving the symptoms of type 2 diabetes. The aim of this project was to further investigate the effects of this bamboo extract on hepatic biotransformation enzymes in both lean and obese mice, as an initial step in the toxicological evaluation of using this traditional medicine in obese/diabetic population.

Materials and methods: Male C57BL/6J mice were randomized to 4 groups and fed standard (10% kcal from fat) diet with or without bamboo extract supplementation at a dose of 10 gram per kilogram diet (n=10 and n=9, respectively), or high fat (45% kcal from fat) diet with or without bamboo extract (n=8 and N=7, respectively). The dietary treatment lasted for 6 months. Subsequently, the activities and expression of the major Phase I and II hepatic biotransformation enzymes were assessed in subcellular fractions from murine livers.

Results: Three groups of mice, lean bamboo extract-supplemented, obese/diabetic, and bamboo extract-supplemented obese/diabetic, showed greater activities of cytochromes P450 1a2 and 3a11 compared to control but no changes in the expression level of these proteins. For Phase II enzymes, bamboo extract supplementation in lean mice caused decreased glutathione-S-transferase activity (−12%) and greater uridine diphosphate glucuronosyltransferase activity (+46%), but had no effect on sulfotransferase activity. Conversely, the obese/diabetic condition itself increased glutathione-S-transferase and uridine diphosphate glucuronosyltransferase activities, but decreased total sulfotransferase activity and sulfotransferase 2a1 expression.

Conclusions: Bamboo extract and obesity/diabetes show significant independent effects on hepatic biotransformation as well as interaction effects in mice. These changes may alter the clearance of endo- and xenobiotics, including bamboo extract itself, hence this effect should be carefully considered in the medicinal application of bamboo extract as it has potential to alter its own metabolism and that of other medications concurrently administered to obese diabetic patients.

1. Introduction

1.1. Traditional use and modern application of bamboo extracts in China

Bamboo is a rich natural resource in China. In traditional Chinese medicine, bamboo leaves are used as a component to reduce the energy of “fire” (an element usually related to inflammation), and treat hypertension, arteriosclerosis, and cardiovascular disease (Yuan, 1983). Besides the medicinal application, bamboo leaves and stems have been traditionally used in family kitchens to enhance the flavor and color of food, especially in the rural areas surrounded by “Bamboo Seas” in southern China. Correlations between the use of bamboo components in cooking processes and generally improved health status of the residents have been observed in some of the so called “bamboo villages”, but solid scientific examinations are yet to be conducted.

Growing from the root of tradition into the industrialized era, China sees the continuous usage of bamboo in modernized Chinese medicine, such as “Zhu Li Kou Fu Ye”, an extract of bamboo leaves inhibiting inflammation in the throat. Moreover, for the purpose of benefiting health and preserving the products from oxidation, bamboo extracts are also used in the beverage and food industries in China.
1.2. Potential anti-diabetic functions of bamboo extract

During the last few years, an ethanol/water extract of bamboo Phyllostachys edulis produced in China has been introduced in the market of the United States as a dietary supplement. Investigations carried out in our laboratory have demonstrated a potent anti-lipotoxicity function of this bamboo extract (BEX) using in vitro models (Panee et al., 2008). Subsequent in vivo studies further revealed that, when used as a dietary supplement in a high fat diet, BEX significantly improved glucose tolerance, inhibited hyperinsulinemia, lowered hepatic fat content and decreased circulating levels of tumor necrosis alpha (a major pro-inflammatory cytokine) in obese C57BL/6j mice (manuscript under preparation). These results indicate that BEX inhibits obesity-associated chronic systemic inflammation and ameliorates the symptoms of type 2 diabetes, suggesting a potential application of this natural product as an anti-diabetic nutraceutical.

1.3. Role of xenobiotic biotransformation enzymes in the safety of nutraceuticals

Xenobiotic biotransformation, mainly carried out in the liver, is a biological process that transforms lipopholic endo- or xenobiotics into hydrophilic substances that can be eliminated from the body, thus avoiding potentially harmful accumulation of the lipopholics (Klaassen, 2001). Phase I enzymes catalyze reactions that usually result in a small increase in hydrophilicity and involve hydrolysis, reduction, and oxidation to expose or introduce a functional group. Of these, the Cytochromes P450 (CYP) are most important (Klaassen, 2001). While many CYPs exist, the main enzymes involved in xenobiotic biotransformation belong to the families CYP1, CYP2, and CYP3 (Klaassen, 2001). Phase II enzymes often use the substrates produced by Phase I reactions and further increase the size and popularity of these compounds for ready excretion from the body. The major Phase II enzymes are uridine diphosphate glucuronosyltransferases (UGT), sulfotransferases (SULT) and glutathione-S-transferases (GST) (Klaassen, 2001).

Phases I and II enzymes can be induced or inhibited by nutraceuticals, with a net result that globalized enzyme induction usually results in greater clearance and elimination while general enzyme inhibition often causes harmful accumulation of chemicals (Martignon and Grothuis, 2006). The effect of nutraceuticals on hepatic biotransforming reactions should be carefully considered during the development of such products.

1.4. Influences of obesity, and diabetes on xenobiotic biotransformation

Physiological factors such as obesity and diabetes can alter the hepatic biotransformation processes and change the metabolism of nutraceuticals and drugs (Ioannides and Barnett, 1999). In humans, obesity is associated with increased CYP2E1 but decreased CYP3A4 activities in the liver (Kotlyar and Carson, 1999; Burton et al., 2005), and with increased Phase II GST, UGT, and SULT activities (Abernethy and Greenblatt, 1986; Blouin et al., 1987; Barnett et al., 1993; Roe et al., 1999). In rodent models of obesity-induced diabetes, decreased hepatic GST activity has been reported (Barnett et al., 1992; Roe et al., 1999). Therefore, special attention is needed when administering nutraceuticals to obese and/or diabetic animals since changes in Phases I and II enzymes can result in altered efficacy and safety of the endogenous compounds (Roe et al., 1999). Additionally, there is further need for defining baseline levels of biotransformation enzymes as well as the independent effects of any compound (e.g. BEX) or disease state (e.g. obesity or type 2 diabetes).

1.5. Aims of this study

The aims of the present study were to assess the effects of BEX dietary supplement and obesity-induced type 2 diabetes on hepatic Phases I and II enzymes, and the potential interaction between the two factors. This is an initial step toward the safety evaluation of BEX in its future nutraceutical application.

2. Material and methods

2.1. Dietary treatments

The following diets were manufactured at Research Diets (New Brunswick, NJ): Lean control diet (10% kcal from fat, cat# D12450B), abbreviated as Lean Ctl; lean diet with BEX supplementation, abbreviated as Lean BEX; high fat diet (45% kcal from fat, cat# D12451), labeled as Obese Ctl; and high fat diet with BEX supplementation, labeled as Obese BEX. The dose of BEX supplementation in both diets was 10 g dry mass per kg of diet.

2.2. Animals

Thirty-four three-week-old male C57BL/6j mice were purchased from the Jackson Laboratory (Bar Harbor, MN) and housed at the University of Hawaii Laboratory Animal Services facility. The animal protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Hawaii. After one week of acclimation with standard laboratory rodent chow, 9 mice were fed Lean Ctl diet (referred to as the Lean Ctl group), 10 mice were fed Lean BEX diet (Lean BEX group), 7 mice were fed Obese Ctl diet (Obese Ctl group), and 8 mice were fed Obese BEX diet (Obese BEX group). The behavior and appearance of all mice appeared normal and there was no observed adverse effect from BEX supplementation. The dietary treatment lasted for 6 months before the mice were sacrificed by CO2 asphyxiation. The livers were excised, snap frozen in liquid nitrogen, and then stored at –80 °C until the time of assay.

2.3. Preparation of liver microsomal and cytosolic fractions

Liver samples were homogenized in a tissue grinder with buffer (0.1 M potassium phosphate, pH 6.5) at a 1:4 (weight:volume) ratio and then centrifuged at 20,000 × g at 4 °C for 20 min. The clear liquid fraction was aliquoted to a clean tube and centrifuged at 100,000 × g at 4 °C for 1 h. The clear cytosolic fraction was aliquoted out and the microsome pellets were resuspended in buffer. Fractions were stored at –80 °C.

2.4. Bicinchoninic acid assay for protein concentration

The protein concentration of microsomal and cytosolic liver fractions were assessed at 1.200 dilution using copper II sulfate solution in bicinchoninic acid with absorbance measured in a spectrophotometer at 562 nm (SpectraMax 340, Molecular Devices, Sunnyvale, CA) as previously described (Smith et al., 1985). Concentration was assigned by comparison to a standard curve of bovine serum albumin fraction V.

2.5. Enzyme activity assays

2.5.1. CYP1a2 (Dutton and Parkinson, 1989)

Microsomes (0.2 mg protein/mL final concentration) were incubated in black 96-well plates in the spectrophotometer at 37 °C for 2 min with 1 μL of 1 mM ethoxyresorufin substrate (in methanol) and 79 μL buffer (0.05 M Tris 25 mM MgCl2, pH 7.4). Then, 10 μL of 2.5 mM NADPH tetrasodium salt was added and fluorescence
measured every 20 s for 10 min at 530/585 nm. All reactions were carried out in triplicate. The activity was determined using a standard curve of resorufin (0–1000 nM). For calculations, production of resorufin was within 10% of ethoxyresorufin concentration.

2.5.2. CYP3A11 (Price et al., 2000)

Microsomes (0.2 mg protein/mL final concentration) were prepared with and without the inhibitor, ketoconazole. Samples were incubated in black 96-well plates in a fluorometer (SpectraMax Gemini XS, Molecular Devices) at 37 °C for 2 min with or without 1 μM of 20 μM ketoconazole, 1 μL of 10 mM 7-benzyloxy-4-trifluoromethylcoumarin (BFC), and 78 μL buffer (0.1 M potassium phosphate 5 mM MgSO4, pH 7.4). An aliquot (10 μL) of 10 mM NADPH was added to all wells and the plate was read fluorescently at 37 °C for 25 min. All reactions were carried out in triplicate. Fluorescence was read at 410/510 nm, and high sensitivity. The activity was determined using a standard curve of 7-ethoxy-4-trifluoromethylcoumarin (HFC) (0–5 μM). For calculations, production of HFC was within 10% of BFC concentration. The final activity of CYP3A11 was calculated by subtracting the rate of activity with inhibitor from the rate of activity without inhibitor.

2.5.3. Total GST (Habig et al., 1974)

Cytosols (0.2 mg protein/mL final concentration) were incubated in optically clear 96-well plates in the spectrophotometer at 37 °C for 2 min with 1 μL of 50 mM l-chloro 2,4-dinitrobenzene (CDNB) substrate (in dimethyl sulfoxide, DMSO) and 79 μL of buffer (0.1 M potassium phosphate, pH 6.5). Then, 10 μL of 10 mM reduced l-glutathione cofactor was added to a final volume of 100 μL. The absorbance at 340 nm was recorded every 10 s for 10 min. All reactions were carried out in triplicate. Specific activity was calculated using an extinction coefficient factor of 9.6 mM/cm.

2.5.4. Total UGT (Collier et al., 2000)

Microsomes (0.1 mg protein/mL final concentration) were incubated in black 96-well plates in the fluorometer at 37 °C for 2 min with 1 μL of Amelatin (50 μg/mg protein in DMSO), 10 μL of 1 mM 4-methyl umbelliferone sodium salt (4 MU) substrate, and 74 μL of buffer (0.1 M Tris–HCl 5 mM MgCl2, pH 7.4). Then, 50 mM uridine 5′-diphosphoglucuronic acid triammonium salt (UDPGA) was added to reach a final volume of 100 μL. Fluorescent intensity was recorded for 10 min at 15 s intervals at 355/460 nm 37 °C. All reactions were carried out in triplicate. Activity of samples was determined by comparison to a standard curve of 4 MU (0–200 μM). For calculations, 4 MU depletion was within 10% of starting 4 MU concentration.

2.5.5. Total SULT (Mulder and Van Doorn, 1975)

Cytosols (2 mg/mL) were incubated for 50 min in a water bath at 37 °C with 210 μL buffer (50 mM potassium phosphate 5 mM MgCl2, pH 6.5), 30 μL of 4 mM 4-nitrophenol (4NP) and 30 μL of 600 μM adenosine 3′-phosphate 5′-phosphosulfate tetralithium salt (PAPS). The reaction was terminated by adding 300 μL of 1 M sodium hydroxide. Then, for each sample, 100 μL was aliquoted in triplicate in clear 96-well plates and absorbance at 400 nm was measured in the spectrophotometer. Substrate depletion was determined using a standard curve of 4NP (0–800 μM). Incubation time was determined using a range-finding curve (20–120 min). For calculations, 4NP depletion was within 10% of starting 4NP concentration.

2.6. Western blotting

Four samples were randomly chosen from each group for western blotting. Sixteen (16) samples from the four experimental groups were loaded in the same Criterion precast 18-well 10% polyacrylamide gel (Biorad, Hercules, CA) for each electrophoresis. Amersham Rainbow Full-Range Marker (GE Healthcare, Piscataway, NJ) was used for molecular weight determination. PVDF membrane (0.45 μM pore size, Millipore Corp., Billerica, MA) was used for protein transfer. The SULT 1a1 mouse monoclonal antibody was purchased from Abnova Corp. (Walnut, CA). SULT 2a1 rabbit polyclonal antibody was purchased from Abcam Inc. (Cambridge, MA). CYP1a2 rabbit polyclonal antibody, CYP3A11 goat polyclonal antibody, UGT1a rabbit polyclonal antibody, and UGT2b goat polyclonal antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Secondary antibodies, biotin–streptavidin peroxidase-conjugated AffiniPure donkey (anti-goat, anti-mouse, anti-rabbit) IgG, and normal donkey serum were purchased from Jackson ImmunoResearch Laboratories, Inc. (West Gove, PA). The detection of the specific binding was accomplished using the 3,3′,5,5′-tetramethylbenzidine (TMB) liquid substrate system. Incubation time ranged from 15 to 60 min depending on speed of the color development.

As a loading control, after the TMB incubation, the PVDF membranes were incubated with Amido Black Stain for 20–35 min for total protein staining, and then with destaining solution for 1.5–2 h to remove the background color. The total protein on the gels was also stained in Coomassie Stain for 40–45 min and then soaked in destaining solution overnight.

ImageJ software was used to determine the density of the bands of specific binding. The loading control was obtained from the average density of three or four bands of different molecular weights from the total protein staining in the membranes or gels. The protein expression was quantified by the ratio between the density of the target protein band and that of the loading control.

2.7. Statistical analysis

Multiple Student’s t-tests or two-way ANOVA were used to determine probability values when appropriate. Data were considered statistically significant when p ≤ 0.05.

3. Results

3.1. Body weight

At the end of the experiment, the body weights of the four groups of mice were: Lean Ctl 28.0 ± 2.8 g, Lean BEX 28.9 ± 3.0 g, Obese Ctl 36.3 ± 3.7 g, and Obese BEX 33.4 ± 4.4 g. BEX supplementation did not significantly affect the body weight at this time point in either the obese or lean mice. However, the high fat diet resulted in a 22% increase of the body weight in comparison to the low fat diet (p < 0.001).

3.2. Phase I enzymes

3.2.1. Protein expression and enzymatic activity of CYP1a2

Western blotting of the protein expression of hepatic CYP1a2 did not show obvious changes among the four experimental groups (Fig. 1A and B). On the other hand, BEX supplementation significantly increased the enzymatic activity of hepatic CYP1a2 by 130% in lean mice and by 61% in obese–diabetic mice (Fig. 1C). Moreover, overall higher CYP1a2 activity was seen in obese–diabetic mice in comparison to the lean animals. The Obese Ctl group showed 620% more activity than the Lean Ctl group, and the Obese BEX group had 403% more activity than the Lean BEX group. These results indicate that both dietary BEX exposure and obesity–diabetes may have contributed to post-translational increase in CYP1a2 activity, and BEX and obesity–diabetes may have had a synergistic effect in increasing CYP1a2 activity, since the presence of both factors...
greatly increased CYP1a2 activity over either condition independently.

3.2.2. Protein expression and enzymatic activity of CYP3a11

When CYP3a11 protein was detected by western blotting, no significant difference in protein expression was observed among the four groups (Fig. 2A and B). Similar to CYP1A2, overall higher CYP3a11 activity was seen in obese mice in comparison to the lean animals (Fig. 2C). The Obese Ctl group showed 446% more activity than the Lean Ctl group, and the Obese BEX group had 203% more activity than the Lean BEX group. BEX supplementation also significantly increased the enzymatic activity of CYP3a11 by 293% in lean mice and by 118% in obese mice. These results indicate that BEX exposure may have contributed to post-translational increase in CYP3a11 activity in both lean and obese–diabetic mice, and in the absence of BEX, obesity–diabetes also may have contributed to an increase in CYP3a11 activity at the post-translational level. Moreover, obesity–diabetes and BEX may have had a synergistic effect in increasing CYP3a11 activity.

3.3. Phase II enzymes

3.3.1. Enzymatic activity of total GST

Overall higher total hepatic GST activity was detected in the obese–diabetic vs. lean mice (Fig. 3). The Obese Ctl group showed a 37% increase in activity compared to the Lean Ctl group, and the Obese BEX group showed 59% more activity than the Lean BEX group. Moreover, BEX supplementation led to a slight but significant 12% decrease in the GST activity in the lean mice, but did not affect the GST activity in the obese–diabetic mice. Due to the lack of suitable antibody, the result of western blotting on total GST was not obtained.

![Fig. 1.](image1.png) Western blot and enzymatic activity of CYP1a2 in mouse liver samples. Panel A shows the bands of CYP1a2 protein detected by a specific antibody and of the loading controls at three molecular weights derived from Amido Black staining of total proteins in the PVDF membrane. Panel B shows the quantification of relative density of the bands; n = 4 in each group. Panel C shows the enzymatic activity of CYP1a2; n = 9 for Lean Ctl group, n = 10 for Lean BEX group, n = 7 for Obese Ctl, and n = 8 for Obese BEX group. Average and SD are shown.

![Fig. 2.](image2.png) Western blot and enzymatic activity of CYP3a11 in mouse liver samples. Panel A shows the bands of CYP3a11 protein detected by a specific antibody and of the loading controls at three molecular weights derived from Amido Black staining of total proteins in the PVDF membrane. Panel B shows the quantification of relative density of the bands; n = 4 in each group. Panel C shows the enzymatic activity of CYP3a11; n = 9 for Lean Ctl group, n = 10 for Lean BEX group, n = 6 for Obese Ctl, and n = 8 for Obese BEX group. Average and SD are shown.
3.3.2. Protein expression of UGT1a and 2b and enzymatic activity of total UGT

The protein expression of two sub-families of the UGT family, UGT1a (Fig. 4A and B) and UGT2b (Fig. 4C and D), was detected by western blotting. No obvious change in the protein levels was observed among the experimental groups. However, overall higher total UGT activity was seen in obese–diabetic mice in comparison to the lean animals (Fig. 4E). The Obese Ctl group showed 102% more activity than the Lean Ctl group, and the Obese BEX group had 71% more activity than the Lean BEX group. BEX supplementation caused a significant 46% increase of the total UGT activity in lean mice, and a non-significant 23% increase in the obese–diabetic mice. Based on substrate affinity, the total UGT activity is attributable mainly to UGT1a activity. Therefore, dietary BEX and obesity–diabetes seem to have contributed to post-translational increases in the activities of (but may not limited to) the UGT1a sub-family.

3.3.3. Protein expression of SULT1a1 and 2a1 and enzymatic activity of total SULT

Western blotting showed no differences at the protein level of SULT1a1 among the experimental groups (Fig. 5A and B). Interestingly, the protein expression of SULT2a1 was significantly inhibited in the obese–diabetic mice compared to the lean mice (Fig. 5C and D). Likewise, there was a significant decrease in the enzymatic activity of total hepatic SULT in the obese–diabetic mice (Fig. 5E). The Obese Ctl group showed an 83% decrease from the Lean Ctl group, and the Obese BEX group had 77% less activity than the Lean BEX group. Although it is difficult to estimate how much of the total SULT activity is attributable to the SULT2a1 isoform, it is likely that the down-regulation of SULT2a1 protein expression in the livers of obese–diabetic mice has at least partially contributed to the decreased total SULT activity. On the other hand, BEX supplementation showed no impact on the protein expression and enzymatic activities of the SULTs examined.

4. Discussion

Dietary components and pathophysiological conditions, such as obesity and diabetes, play important roles in modulating hepatic xenobiotic biotransformation enzymes. Any changes in hepatic Phases I and II enzymes may impact the metabolism of endo- and xenobiotics, which ultimately can affect the efficacy and safety of therapeutic and endogenous agents.
The current study demonstrated that BEX exposure and obesity–diabetes were separately associated with increased CYP1a2 and CYP3a11 activity. In addition, BEX and obesity–diabetes appear to have a synergistic effect in up-regulating both CYP1a2 and CYP3a11 since the presence of both factors showed a greater increase in CYP activity over either condition independently. Because activity increases were not accompanied by measurable increases in CYP protein, this up-regulation may be due to post-translational regulation and modifications.

Since mice in the present study were both obese and diabetic, it is likely that these two conditions interacted. This statement is strengthened by results presented herein that are consistent with previous studies reporting greater CYP3a activity in type 1 diabetic rats (Barnett et al., 1990a,b; Ioannides and Barnett, 1999), and another study reporting no changes in CYP1a2 or CYP3a protein expression in genetically obese Zucker rats or in normal Zucker rats fed high-fat diet (Khemawoot et al., 2007). Roe et al. (1999) reported that hepatic CYP1a activity was significantly decreased in genetically obese–diabetic mice (Roe et al., 1999). For the convenience of comparison, previous studies using rodent models investigating the influences of obesity and/or diabetes on hepatic Phases I and II enzymes are summarized in Table 1. Future studies should be designed to distinguish between the differential effects of diabetes and obesity on CYP enzyme, and to delineate their regulatory mechanisms.

Notably BEX upregulates the activities of hepatic CYP enzymes in lean and especially in obese mice. This effect will subsequently increase the metabolic rate of an array of endo- and xenobiotics, potentially including those of therapeutic drugs and BEX itself as a dietary supplement. As a result, during the course of treatment, the beneficial effect of BEX may be gradually compromised due to a faster reaction with the Phase I enzymes. The following approaches may be considered to address this problem in general: (i) increase the dose to compensate for a greater metabolic rate, but this may further stimulate the CYP activities forming a vicious circle; (ii) periodical administration, allow intervals to decrease the hepatic CYP activities; and (iii) remove impurities that may be responsible for the increase of the enzyme activities.

Furthermore, Phase I reactions usually result in reactive metabolites, which, if not conjugated by Phase II enzymes in time, can be carcinogenic. On the other hand, up-regulation of CYP1a2 may be beneficial by increasing the detoxification and elimination of harmful compounds, as has been shown for black tea which up-regulated hepatic CYP1a2 expression and activity leading to increased urinary excretion of mutagens (Yoxall et al., 2004). Thus the real result of the up-regulation of the Phase I enzyme activities depends on the nature of the substrates and the catalyzing capacity of the Phase II enzymes involved in the subsequent reactions.

The effects of obesity and diabetes on hepatic GST expression and activity are controversial (Kim et al., 2003). The present study showed that the total hepatic GST activity increased in the
<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Animals</strong></td>
</tr>
<tr>
<td>Zucker rat</td>
</tr>
<tr>
<td>Rat</td>
</tr>
<tr>
<td>Ob/Jc mouse</td>
</tr>
<tr>
<td>BioBreeding/Worcester rat</td>
</tr>
</tbody>
</table>

* No change.

**Concluding remarks**

This study investigated the influences of both BEX supplementation and obese–diabetic condition on the protein expression and enzymatic activities of hepatic xenobiotics biotransforming enzymes in male mice. It was found that obesity–diabetes upregulated the activities of CYP1a2, CYP3a11, GST, and UGT, but decrease that of SULT; BEX alone, and in synergy with obesity–diabetes, greatly enhanced the activities of Phase I enzymes, but had less effect on Phase II enzymes in general. Interestingly, the changes in activity observed were rarely correlated with changes in enzyme protein level, with SULT2a1 as an exception.

5. Concluding remarks

This study investigated the influences of both BEX supplementation and obese–diabetic condition on the protein expression and enzymatic activities of hepatic xenobiotics biotransforming enzymes in male mice. It was found that obesity–diabetes upregulated the activities of CYP1a2, CYP3a11, GST, and UGT, but decrease that of SULT; BEX alone, and in synergy with obesity–diabetes, greatly enhanced the activities of Phase I enzymes, but had less effect on Phase II enzymes in general. Interestingly, the changes in activity observed were rarely correlated with changes in enzyme protein level, with SULT2a1 as an exception.
In summary, BEX as a dietary supplement had a minimal inhibitory effect on the enzymes examined, and therefore is not likely to inhibit the metabolism of itself or other endo- and xenobiotics in the liver. The remarkable increases of Phase I enzyme activities induced by BEX and obesity–diabetes may be useful if they correspond to greater detoxification of pro-carcinogens (Stedman et al., 2004; Yoxall et al., 2004), although they may also facilitate transformation of therapeutic drugs and BEX itself, thereby decreasing biological efficacy. Furthermore, increases of UGT and GST activities in the obese–diabetic mice contrast with lowered activity of SULT enzymes. The greater UGT activity noted may be particularly essential when BEX is introduced due to its slight inhibitory effect on GST activity in lean mice. However, variance caused by species and gender should be considered for any general application of these results (Tabrett and Coughtrie, 2003; Hayes et al., 2005; Yoshinari et al., 2006; Braeuning et al., 2009).

The changes in hepatic xenobiotic biotransformation observed due to BEX supplementation are known to occur with several clinically used drugs and other natural and non-natural products. Hence, examination of these properties is critical in the pre-clinical pharmacological and toxicological safety evaluation of new drugs and compounds, including BEX. Care needs to be taken for future pharmacokinetic and dosing studies of BEX to assess the effects of induced CYPs (particularly Cyp3a), however; similar to other clinically-used drugs such as Carbamazepine, enzyme induction by drugs and nutraceuticals does not absolutely preclude drug development and application.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Acknowledgement

This study was made possible by grant numbers R21 AT003874-02 (Panee) from the National Center for Complementary and Alternative Medicine (NCCAM); R21 AT005139-01 (Panee) from NCCAM and the Office of Research on Women’s Health (ORWH), G12RR003061 (RMI Program) from NCCR, and 5P20 MD000173-02 from NCMDH. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM, ORWH, NCCR, NCMDH, or the National Institute of Health.

References
